Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
75,239 questions in 5,342 reviews
current versionsNo studies 15,213 · 20.2%Ungraded 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings table ‐ Metformin vs megestrol Regression of endometrial hyperplasia (with or without atypia) to proliferative, secretory, or atrophic endometrium · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 4.89 [1.56, 15.32] | 2 studies · 83 participants | Very low |
Summary of findings table ‐ Metformin + megestrol vs megestrol Progression of endometrial hyperplasia to endometrial cancer · endometrial hyerplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 7.96 [0.16, 402.02] | 3 studies · 156 participants | Very low |
Summary of findings table ‐ Metformin + megestrol vs megestrol Hysterectomy rate · endometrial hyerplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 7.39 [0.15, 372.38] | 2 studies · 72 participants | Very low |
Summary of findings table ‐ Metformin + megestrol vs megestrol Abnormal uterine bleeding ‐ not measured · endometrial hyerplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Metformin + megestrol vs megestrol Health‐related quality of life (HRQoL) ‐ not measured · endometrial hyerplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Metformin + megestrol vs megestrol Adverse effects during treatment · endometrial hyerplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | 1 study · 8 participants | Very low |
Summary of findings table ‐ Metformin + levonorgestrel (intrauterine system) vs levonorgestrel intrauterine system Regression of endometrial hyperplasia (with or without atypia) to proliferative, secretory, or atrophic endometrium · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 3.42 [0.13, 88.4] | 1 study · 46 participants | Very low |
Summary of findings table ‐ Metformin + levonorgestrel (intrauterine system) vs levonorgestrel intrauterine system Recurrence of endometrial hyperplasia ‐ not reported · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Metformin + levonorgestrel (intrauterine system) vs levonorgestrel intrauterine system Progression of endometrial hyperplasia to endometrial cancer · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | 1 study · 1 participants | Very low |
Summary of findings table ‐ Metformin + levonorgestrel (intrauterine system) vs levonorgestrel intrauterine system Hysterectomy rate · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 0.12 [0.01, 1.95] | 1 study · 46 participants | Very low |
Summary of findings table ‐ Metformin + levonorgestrel (intrauterine system) vs levonorgestrel intrauterine system Abnormal uterine bleeding · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 0.61 [0.16, 2.27] | 1 study · 49 participants | Very low |
Summary of findings table ‐ Metformin vs megestrol Recurrence of endometrial hyperplasia ‐ not reported · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Summary of findings table ‐ Metformin + levonorgestrel (intrauterine system) vs levonorgestrel intrauterine system Adverse effects during treatment ‐ all effects · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 4 [1.15, 13.9] | 1 study · 51 participants | Very low |
Summary of findings table ‐ Metformin + levonorgestrel (intrauterine system) vs levonorgestrel intrauterine system Adverse effects during treatment ‐ nausea · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 5.11 [1.21, 21.68] | 1 study · 51 participants | Very low |
Summary of findings table ‐ Metformin + levonorgestrel (intrauterine system) vs levonorgestrel intrauterine system Adverse effects during treatment ‐ heaviness in lower abdomen · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 1.38 [0.32, 5.85] | 1 study · 51 participants | Very low |
Summary of findings table ‐ Metformin + levonorgestrel (intrauterine system) vs levonorgestrel intrauterine system Adverse effects during treatment ‐ pain in abdomen · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 0.83 [0.22, 3.18] | 1 study · 51 participants | Very low |
Summary of findings table ‐ Metformin vs megestrol Progression of endometrial hyperplasia to endometrial cancer · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | 2 studies · 2 participants | Very low |
Summary of findings table ‐ Metformin vs megestrol Hysterectomy rate · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 0.91 [0.05, 15.52] | 2 studies · 85 participants | Very low |
Summary of findings table ‐ Metformin vs megestrol Abnormal uterine bleeding · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 0.91 [0.05, 15.52] | 1 study · 44 participants | Very low |
Summary of findings table ‐ Metformin vs megestrol Health‐related quality of life (HRQoL) ‐ not measured · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Metformin vs megestrol Adverse effects during treatment ‐ not reported · endometrial hyperplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Metformin + megestrol vs megestrol Regression of endometrial hyperplasia (with or without atypia) to proliferative, secretory, or atrophic endometrium · endometrial hyerplasia Metformin for endometrial hyperplasia (2024) · Cochrane | OR 3.27 [1.65, 6.51] | 4 studies · 258 participants | Low |
Summary of findings table ‐ Metformin + megestrol vs megestrol Recurrence of endometrial hyperplasia · endometrial hyerplasia Metformin for endometrial hyperplasia (2024) · Cochrane | no estimate extracted | 1 study · 8 participants | Very low |
Summary of findings table ‐ Probiotics vs placebo Proven sepsis (positive bacterial culture, local or systemic) · neonates born from 35 weeks of gestation who have underdone gastrointestinal surgery Probiotics for the postoperative management of term neonates after gastrointestinal surgery (2024) · Cochrane | OR 0.64 [0.16, 2.55] | 1 study · 61 participants | Low |
Summary of findings table ‐ Probiotics vs placebo All‐cause neonatal mortality (28 days) · neonates born from 35 weeks of gestation who have underdone gastrointestinal surgery Probiotics for the postoperative management of term neonates after gastrointestinal surgery (2024) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Summary of findings table ‐ Probiotics vs placebo Time to full enteral feeds in daysScale from: 0 to 100 · neonates born from 35 weeks of gestation who have underdone gastrointestinal surgery Probiotics for the postoperative management of term neonates after gastrointestinal surgery (2024) · Cochrane | no estimate extracted | 1 study · 61 participants | Low |
Summary of findings table ‐ Probiotics vs placebo All‐cause mortality prior to discharge · neonates born from 35 weeks of gestation who have underdone gastrointestinal surgery Probiotics for the postoperative management of term neonates after gastrointestinal surgery (2024) · Cochrane | no estimate extracted | 1 study · 61 participants | Ungraded |
Summary of findings table ‐ Probiotics vs placebo Non‐pathogenic intestinal microflora (relative abundance) · neonates born from 35 weeks of gestation who have underdone gastrointestinal surgery Probiotics for the postoperative management of term neonates after gastrointestinal surgery (2024) · Cochrane | no estimate extracted | 1 study · 39 participants | Low |
Intervention NR Body weight change (kg) · participants living with overweight or obesity Calcium supplementation for people with overweight or obesity (2024) · Cochrane | no estimate extracted | 17 studies · 1317 participants | Low |
Intervention NR Health‐related quality of life · participants living with overweight or obesity Calcium supplementation for people with overweight or obesity (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · participants living with overweight or obesity Calcium supplementation for people with overweight or obesity (2024) · Cochrane | no estimate extracted | 5 studies · 854 participants | Low |
Intervention NR All‐cause mortality · participants living with overweight or obesity Calcium supplementation for people with overweight or obesity (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Morbidity · participants living with overweight or obesity Calcium supplementation for people with overweight or obesity (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Anthropometric measures other than body weight a) BMI b) Waist circumference c) Fat mass · participants living with overweight or obesity Calcium supplementation for people with overweight or obesity (2024) · Cochrane | no estimate extracted | 9 studies · 731 participants | Moderate |
Structured risk assessment vs standard professional care Scientific behaviour: aggression – clinically important change in aggressive/violent behaviour, as defined by the individual studies · aggressive behaviour in schizophrenia Risk assessment for aggressive behaviour in schizophrenia (2024) · Cochrane | RR 0.59 [0.41, 0.85] | 1 study · 1852 participants | Moderate |
Structured risk assessment vs standard professional care Use of coercive measure: use of seclusion room (time, days) · aggressive behaviour in schizophrenia Risk assessment for aggressive behaviour in schizophrenia (2024) · Cochrane | RR 0.92 [0.27, 3.07] | 1 study · 20 participants | Low |
Structured risk assessment vs standard professional care Use of coercive measure: use of seclusion room (participants) · aggressive behaviour in schizophrenia Risk assessment for aggressive behaviour in schizophrenia (2024) · Cochrane | RR 1.83 [0.39, 8.7] | 1 study · 20 participants | Low |
Structured risk assessment vs standard professional care Use of coercive measure: use of seclusion room (incidents) · aggressive behaviour in schizophrenia Risk assessment for aggressive behaviour in schizophrenia (2024) · Cochrane | RR 1.63 [0.49, 5.47] | 1 study · 20 participants | Low |
Structured risk assessment vs standard professional care Adverse effects (escape) · aggressive behaviour in schizophrenia Risk assessment for aggressive behaviour in schizophrenia (2024) · Cochrane | RR 0.2 [0.01, 4.11] | 1 study · 200 participants | Very low |
Structured risk assessment vs standard professional care Adverse effects (fall down) · aggressive behaviour in schizophrenia Risk assessment for aggressive behaviour in schizophrenia (2024) · Cochrane | RR 0.33 [0.04, 3.15] | 1 study · 200 participants | Very low |
Structured risk assessment vs standard professional care Adverse effects (choking) · aggressive behaviour in schizophrenia Risk assessment for aggressive behaviour in schizophrenia (2024) · Cochrane | RR 0.2 [0.01, 4.11] | 1 study · 200 participants | Very low |
Mindfulness‐enhanced parent training vs no‐treatment, waitlist, or attentional control Child emotional and behavioural adjustment; postintervention · parents of children between the ages of 0 and 18 years Mindfulness‐enhanced parenting programmes for improving the psychosocial outcomes of children (0 to 18… (2024) · Cochrane | no estimate extracted | 3 studies · 270 participants | Very low |
Mindfulness‐enhanced parent training vs parent training Parenting skills; postintervention · parents of children between the ages of 0 and 18 years Mindfulness‐enhanced parenting programmes for improving the psychosocial outcomes of children (0 to 18… (2024) · Cochrane | no estimate extracted | 3 studies · 319 participants | Very low |
Mindfulness‐enhanced parent training vs parent training Parental depression or anxiety; postintervention · parents of children between the ages of 0 and 18 years Mindfulness‐enhanced parenting programmes for improving the psychosocial outcomes of children (0 to 18… (2024) · Cochrane | no estimate extracted | 1 study · 45 participants | Very low |
Mindfulness‐enhanced parent training vs parent training Parenting stress; postintervention · parents of children between the ages of 0 and 18 years Mindfulness‐enhanced parenting programmes for improving the psychosocial outcomes of children (0 to 18… (2024) · Cochrane | no estimate extracted | 3 studies · 150 participants | Low |
Mindfulness‐enhanced parent training vs parent training Parent mindfulness; postintervention · parents of children between the ages of 0 and 18 years Mindfulness‐enhanced parenting programmes for improving the psychosocial outcomes of children (0 to 18… (2024) · Cochrane | no estimate extracted | 4 studies · 412 participants | Very low |
Mindfulness‐enhanced parent training vs parent training Measures of self‐compassion · parents of children between the ages of 0 and 18 years Mindfulness‐enhanced parenting programmes for improving the psychosocial outcomes of children (0 to 18… (2024) · Cochrane | no estimate extracted | NR | No studies |
Mindfulness‐enhanced parent training vs no‐treatment, waitlist, or attentional control Adverse effects · parents of children between the ages of 0 and 18 years Mindfulness‐enhanced parenting programmes for improving the psychosocial outcomes of children (0 to 18… (2024) · Cochrane | no estimate extracted | NR | No studies |
Mindfulness‐enhanced parent training vs no‐treatment, waitlist, or attentional control Parenting skills; postintervention · parents of children between the ages of 0 and 18 years Mindfulness‐enhanced parenting programmes for improving the psychosocial outcomes of children (0 to 18… (2024) · Cochrane | no estimate extracted | 3 studies · 587 participants | Very low |
Mindfulness‐enhanced parent training vs no‐treatment, waitlist, or attentional control Parental depression or anxiety; postintervention · parents of children between the ages of 0 and 18 years Mindfulness‐enhanced parenting programmes for improving the psychosocial outcomes of children (0 to 18… (2024) · Cochrane | no estimate extracted | 1 study · 75 participants | Very low |